ImmuCell Corporation (NASDAQ:ICCC) is set to announce third quarter earning results on Thursday 12th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, ICCC to report 3Q20 loss of $ 0.08 per share from revenue of $ 3.27 million.
For the full year, analysts anticipate top line of $ 15.14 million, while looking forward to loss of $ 0.24 per share bottom line.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 3.70 million ~ $ 3.70 million
Click Here For More Historical Outlooks Of ImmuCell Corporation
Previous Quarter Performance
ImmuCell Corporation disclosed loss for the second quarter of $ 0.11 per share, from the revenue of $ 2.97 million. Street analysts expected ImmuCell Corporation to report loss of $ 0.10 per share on revenue of $ 3000.00 million for the second quarter. The bottom line results missed street analysts by $ 0.01 or 10 percent, at the same time, top line results fell short of analysts by $ 2 million or 99.9 percent.
Stock Performance
Shares of ImmuCell Corporation traded low $ -0.01 or -0.18 percent on Wednesday, reaching $ 5.46 with volume of 3.90 thousand shares. ImmuCell Corporation has traded high as $ 5.63 and has cracked $ 5.46 on the downward trend
The closing price of $ 5.46, representing a 47.84 % increase from the 52 week low of $ 3.70 and a 32.72 % decrease over the 52 week high of $ 8.13.
The company has a market capital of $ 39.38 million and is part of the Healthcare sector and Biotechnology industry.
ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus.
